Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
M4 Receptors
More Information »M4 receptors are members of the G-protein-coupled receptor (GPCR) family which are found mostly bound to Gi proteins, generally leading to inhibitory effects. They are one of five muscarinic receptors that act to control the metabotropic functions of acetylcholine in the CNS.
M4 Receptor Products
Antagonists |
|
Cat.No. |
Product Name / Activity |
| 1671 | PD 102807 |
| Selective M4 antagonist | |
| 0909 | Tropicamide |
| Selective M4 muscarinic antagonist | |
Modulators |
|
Cat.No. |
Product Name / Activity |
| 3141 | VU 10010 |
| Selective allosteric potentiator of M4 receptors | |
| 3383 | VU 152100 |
| Positive allosteric modulator of M4 receptors | |
Related Categories
Quick Order
Find multiple products by catalog number
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
The Neurobiology of Alzheimer's Disease
Written by Alan Palmer
'The Neurobiology of Alzheimer's Disease' summarizes structural and functional changes observed in the progression of AD.
Regulation of Vascular Reactivity by GPCRs
Written by J.J. Maguire and A.P. Davenport
'Regulation of Vascular Reactivity by G-protein-coupled Receptors' summarizes the key GPCRs regulating vascular reactivity.
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.